CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
GlycoBoost focuses on enhancing the design of monoclonal antibodies by ensuring consistent and precise N-glycan patterns. This innovative approach aims to improve the safety and efficacy of treatments for autoimmune diseases, leveraging advanced cell engineering and glycoanalytical techniques.
Biologics comprise a $511B market of advanced therapeutics that are used to treat cancer, autoimmune diseases, infectious diseases and beyond.
Two thirds of biologics are decorated with sugar molecules attached to the therapeutics, including all antibody therapeutics, called monoclonal antibodies (mAbs).
These sugar molecules are known as N-glycans and are vitally important for therapeutic safety and efficacy.
To date, the N-glycans are poorly controlled and, as such, display highly heterogene…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Croatia, OSIJEK
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
